"Dopamine Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME.
| Descriptor ID |
D018492
|
| MeSH Number(s) |
D27.505.519.625.150.175 D27.505.696.577.150.175
|
| Concept/Terms |
Dopamine Antagonists- Dopamine Antagonists
- Dopaminergic Antagonists
- Dopamine Blockers
- Blockers, Dopamine
- Antagonists, Dopamine Receptor
- Receptor Antagonists, Dopamine
- Antagonists, Dopaminergic
- Dopamine Receptor Antagonists
- Antagonists, Dopamine
|
Below are MeSH descriptors whose meaning is more general than "Dopamine Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Dopamine Antagonists".
This graph shows the total number of publications written about "Dopamine Antagonists" by people in this website by year, and whether "Dopamine Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 1 | 1 | 2 |
| 2009 | 1 | 1 | 2 |
| 2010 | 1 | 1 | 2 |
| 2011 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dopamine Antagonists" by people in Profiles.
-
Ruzek M, Richman P, Eskin B, Allegra JR. ED treatment of migraine patients has changed. Am J Emerg Med. 2019 Jun; 37(6):1069-1072.
-
Collins LE, Sager TN, Sams AG, Pennarola A, Port RG, Shahriari M, Salamone JD. The novel adenosine A2A antagonist Lu AA47070 reverses the motor and motivational effects produced by dopamine D2 receptor blockade. Pharmacol Biochem Behav. 2012 Jan; 100(3):498-505.
-
Millan MJ, Buccafusco JJ, Loiseau F, Watson DJ, Decamp E, Fone KC, Thomasson-Perret N, Hill M, Mocaer E, Schneider JS. The dopamine D3 receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures. Int J Neuropsychopharmacol. 2010 Sep; 13(8):1035-51.
-
Silberstein SD. Association between restless legs syndrome and migraine. J Neurol Neurosurg Psychiatry. 2010 May; 81(5):473-5.
-
Williams SN, Undieh AS. Brain-derived neurotrophic factor signaling modulates cocaine induction of reward-associated ultrasonic vocalization in rats. J Pharmacol Exp Ther. 2010 Feb; 332(2):463-8.
-
Dusitanond P, Young WB. Neuroleptics and migraine. Cent Nerv Syst Agents Med Chem. 2009 Mar; 9(1):63-70.
-
Guilarte TR, Chen MK, McGlothan JL, Verina T, Wong DF, Zhou Y, Alexander M, Rohde CA, Syversen T, Decamp E, Koser AJ, Fritz S, Gonczi H, Anderson DW, Schneider JS. Nigrostriatal dopamine system dysfunction and subtle motor deficits in manganese-exposed non-human primates. Exp Neurol. 2006 Dec; 202(2):381-90.
-
Bustillo J, Barrow R, Paz R, Tang J, Seraji-Bozorgzad N, Moore GJ, Bolognani F, Lauriello J, Perrone-Bizzozero N, Galloway MP. Long-term treatment of rats with haloperidol: lack of an effect on brain N-acetyl aspartate levels. Neuropsychopharmacology. 2006 Apr; 31(4):751-6.
-
Tietjen GE, Athanas K, Utley C, Herial NA, Khuder SA. The combination of naratriptan and prochlorperazine in migraine treatment. Headache. 2005 Jun; 45(6):751-3.
-
Young WB, Piovesan EJ, Biglan KM. Restless legs syndrome and drug-induced akathisia in headache patients. CNS Spectr. 2003 Jun; 8(6):450-6.